At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
teverelix TFA 120 mg +1 moredrug
Likely dose
teverelix TFA 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH Antagonist, in Participants With Advanced Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating teverelix TFA 120 mg and teverelix TFA 180 mg for Prostatic Adenoma. Completed, enrolled 50 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Adenoma
CountriesLithuania
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartMar 2021
Primary CompletionDec 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedJan 5, 2021
Enrollment StartMar 4, 2021
Primary CompletionDec 5, 2022
Study CompletionFeb 6, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.5 years ago
Interventions
teverelix TFA 120 mgdrug
Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
teverelix TFA 180 mgdrug
Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24